Erratum: Natural History of Non-Small-Cell Lung Cancer with Bone Metastases (Scientific Reports (2015) 5 (18670) DOI: 10.1038/srep18670);Natural History of Non-Small-Cell Lung Cancer with Bone Metastases

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Daniele, Santini ^a   Sandro, Barni ^b   Salvatore, Intagliata ^a   Alfredo, Falcone ^c   Francesco, Ferraù ^d   Domenico, Galetta ^e   Luca, Moscetti ^f   Nicla, La Verde ^g   Toni, Ibrahim ^h   Fausto, Petrelli ^b   Enrico, Vasile ^c   Laura, Ginocchi ^c   Davide, Ottaviani ⁱ   Flavia, Longo ^j   Cinzia, Ortega ^k   Antonio, Russo ^l   Giuseppe, Badalamenti ^l   Elena, Collovà ^m   Gaetano, Lanzetta ⁿ   Giovanni, Mansueto ^o   Vincenzo, Adamo ^p,q   Filippo, De Marinis ^r   Antonietta, Satolli Maria ^s   Flavia, Cantile ^t   Andrea, Mancuso ^u   Tanca, Francesca Maria ^v   Raffaele, Addeo ^w   Marco, Russano ^a   Sterpi, M ^a   Francesco, Pantano ^a   Bruno, Vincenzi ^a   Giuseppe, Tonini ^a   more..

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b TREVIGLIO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PISA   (Italy)

^d S Vincenzo Hospital   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f BELCOLLE HOSPITAL   (Italy)

^g FATEBENEFRATELLI HOSPITAL   (Italy)

^h DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

ⁱ GRADENIGO HOSPITAL   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k CANDIOLO CANCER INSTITUTE   (Italy)

^l UNIVERSITY OF PALERMO   (Italy)

^m Ospedale Civile di Legnano   (Italy)

ⁿ Istituto Neurotraumatologico Italiano   (Italy)

^o Section of Nephrology Umberto I   (Italy)

^p UNIVERSITY OF MESSINA   (Italy)

^q Azienda Ospedaliera Ospedali Riuniti Papardo Piemonte   (Italy)

^r EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^s UNIVERSITY OF TURIN   (Italy)

^t SECOND UNIVERSITY OF NAPLES   (Italy)

^u SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^v UNIVERSITY OF CAGLIARI   (Italy)

^w ASL NA2 NORD   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; BONE TUMOR; CLINICAL TRIAL; DISEASE COURSE; FEMALE; HUMAN; LUNG TUMOR; MALE; MIDDLE AGED; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PATHOLOGY; SECONDARY; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84951835988     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep22205     Document Type: Erratum

References (17)

1. Siegel, R., Ma, J., Zou, Z. & Jemal, A. Cancer Statistics, 2014. CA Cancer J Clin. 64, 9-29 (2014)
2. Sandler, A. et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 355, 2542-50 (2006)
3. Johnson, B. E. et al. A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC). J Clin Oncol ASCO Annual Meeting Abstracts. 31, 8019 (2013)
4. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors. A randomised, Phase III, double blind, placebo-controlled trial. Cancer. 100, 2613-2621 (2004).
5. Price, N., Belani, C. P. & Jain, V. K. Biphosphonates to prevent skeletal morbidity in patients with lung cancer with bone metastases. Clin Lung Cancer. 5, 267-269 (2004)
6. Kosteva, J. & Langer, C. Incidence and distribution of skeletal metastases in NSCLC in the era of PET. Lung Cancer. 46 (Suppl 1), S45 (2004)
7. Coleman, R. E. Skeletal complications of malignancy. Cancer. 890, 1588-94. doi: 10.1002/(SICI)1097-0142(19971015) (1997)
8. O'Connell, J. P. et al. Frequency and prognostic importance of pretreatment clinical characteristics in patients with advanced nonsmall-cell lung cancer treated with combination chemotherapy. J Clin Oncol. 4, 1604-14 (1986)
9. Weinfurt, K. P. et al. The significance of skeletal related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol. 16, 579-584 (2005)
10. Lipton, A. et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastasis: long term follow-up of two randomized, placebo-controlled trials. Cancer. 88, 1082-1090 (2000).
11. Coleman, R. E. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev. 27, 165-176 doi: 10.1053/CTRV.2000.0210 (2011).
12. Coleman, R. E. Biphosphonates: clinical experience. Oncologist. 9 (Suppl 4),14-27 (2004)
13. Kaplan, E. L. & Meier, P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53, 457-481 doi: 10.1080/01621459.1958.10501452 (1958)
14. Peto, R. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 35, 1-39. (1977)
15. Tsuya, A., Kurata, T., Tamura, K. & Fukuoka, M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer. 57, 229-232 (2007)
16. Rosen, L. S. et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 100, 2613-2621 (2004).
17. Scagliotti, G. V. et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid. Subgroup analysis from a randomized phase 3 study. J Thoracic Oncol. 7, 1823-1829 (2012).